Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
COAGthis companyHemab Therapeutics Holdings, Inc. Common Stock	$45.01	-14.59×	-5.28×	0×	-12.12×	-92.6%	0.0%	0.0%	0.0%	36.2%	-37.8%	-6.6%	-0.01×	1.24×	0×	18.03×	0.0%	—	—	2	C+
DMRADamora Therapeutics, Inc.	$24.20	-0.15×	0.13×	0×	1.08×	776.2%	0.0%	0.0%	0.0%	-87.3%	-87.7%	-21.4%	0×	1.23×	0×	12.98×	0.0%	3	26.87	1	D+
IRONDisc Medicine, Inc.	$79.88	-13.21×	3.79×	0×	-13.05×	-97.1%	0.0%	0.0%	0.0%	-28.7%	-30.6%	-6.5%	0×	0.43×	-65.43×	21.94×	0.0%	1	18.78	2	C
RLYBRallybio Corporation	$15.81	-3.45×	0.53×	36.02×	0.01×	-35.3%	89.3%	-3270.9%	-1046.4%	-15.5%	-48.3%	-96.5%	0×	1.12×	0×	14.5×	0.0%	6	13.79	4	A
Peer median	—	-3.45×	0.53×	0×	0.01×	-35.3%	0.0%	0.0%	0.0%	-28.7%	-48.3%	-21.4%	0×	1.12×	0×	14.5×	0.0%	3	18.78	2	—